Department of Radiology, Addenbrookes Hospital, Cambridge, United Kingdom.
Int J Gynecol Cancer. 2010 Aug;20(6):971-8. doi: 10.1111/IGC.0b013e3181e0a353.
The Gynaecological Cancer InterGroup conducts collaborative trials in gynecologic cancer and also aims to develop standards that can be used to strengthen all aspects of study methodology. There is an urgent need to develop more refined imaging end points that can be used as early treatment response biomarkers in ovarian cancer. Therefore, the Gynaecological Cancer InterGroup commissioned an expert position paper on the role of functional imaging as an end point in clinical trials in ovarian cancer. In this position paper, we state the limitation of current anatomical imaging methods used in clinical trials, highlight the potential of functional imaging, and provide key recommendations on the use of functional imaging as an end point in ovarian cancer clinical trials.
妇科癌症协作组开展妇科癌症协作试验，旨在制定可用于加强研究方法学各个方面的标准。迫切需要开发更精细的成像终点，可作为卵巢癌早期治疗反应的生物标志物。因此，妇科癌症协作组委托撰写了一份关于功能成像作为卵巢癌临床试验终点作用的专家立场文件。在本立场文件中，我们指出了临床试验中当前使用的解剖成像方法的局限性，强调了功能成像的潜力，并就功能成像作为卵巢癌临床试验终点的应用提供了关键建议。
